Small Cell Lung Cancer Indication

Immune Checkpoint Inhibitors (ICIs) Pipeline Landscape

SCLC is an unforgiving, highly aggressive variant of lung cancer. It accounts for approximately 15% of the lung cancer cases globally and is also a major cause of cancer-related deaths. ​The chemotherapy has been the mainstay in SCLC management. While response rate to chemotherapy is high, notably, almost all patients relapse after few months (PFS is typically 4.0 - 5.5 months).

Read More